Gut - <https://pubmed.ncbi.nlm.nih.gov/?term=%22Gut%22%5Bjour%5D> - <https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Gut%22[Title+Abbreviation]> - <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#>
. 2020 Jun 4;gutjnl-2020-321852. doi: 10.1136/gutjnl-2020-321852. Online ahead of print. Famotidine Use and Quantitative Symptom Tracking for COVID-19 in Non-Hospitalised Patients: A Case Series Tobias Janowitz <https://pubmed.ncbi.nlm.nih.gov/?term=Janowitz+T&cauthor_id=32499303> 1 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-1> 2 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-2> , Eva Gablenz <https://pubmed.ncbi.nlm.nih.gov/?term=Gablenz+E&cauthor_id=32499303> 3 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-3> 4 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-4> , David Pattinson <https://pubmed.ncbi.nlm.nih.gov/?term=Pattinson+D&cauthor_id=32499303> 5 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-5> , Timothy C Wang <https://pubmed.ncbi.nlm.nih.gov/?term=Wang+TC&cauthor_id=32499303> 6 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-6> , Joseph Conigliaro <https://pubmed.ncbi.nlm.nih.gov/?term=Conigliaro+J&cauthor_id=32499303> 7 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-7> 8 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-8> , Kevin Tracey <https://pubmed.ncbi.nlm.nih.gov/?term=Tracey+K&cauthor_id=32499303> 9 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-9> , David Tuveson <https://pubmed.ncbi.nlm.nih.gov/?term=Tuveson+D&cauthor_id=32499303> 1 <https://pubmed.ncbi.nlm.nih.gov/32499303/?fbclid=IwAR1tIe1Z-Z3iyPmcFH8iBFElVFUaBVOmw-otpJqot19TueKaXZh1jBRovzc#affiliation-1> https://pubmed.ncbi.nlm.nih.gov/32499303/ *Abstract* *Objective: *Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose famotidine orally. *Design: *Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared. *Results: *Ten consecutive patients with COVID-19 who self-administered high-dose oral famotidine were identified. The most frequently used famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5-21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting famotidine. The combined symptom score improved significantly within 24 hours of starting famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased. *Conclusions: *The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19. -- If you appreciate News From Underground, please consider making a donation — either a one-time gift or a monthly subscription: http://markcrispinmiller.com/support/ Thank you for your support. Ways to unsubscribe: 1) send a blank email to [email protected] PLEASE NOTE: you must unsubscribe using the SAME email with which you subscribed 2) go to http://groups.google.com/group/newsfromunderground and click on the "Unsubscribe or change membership" link in the yellow bar at the top of the page, then click the "Unsubscribe" button on the next page. For more News From Underground, visit http://markcrispinmiller.com --- You received this message because you are subscribed to the Google Groups "News From Underground" group. To unsubscribe from this group and stop receiving emails from it, send an email to [email protected]. To view this discussion on the web visit https://groups.google.com/d/msgid/newsfromunderground/CAGxB6W_TMSB2XoO9dZEYKfM%2B1XOATPB7fE-TUphn%2B4dhcc_tVQ%40mail.gmail.com.
